Your browser doesn't support javascript.
loading
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa, Luciano J; Lin, Yi; Cornell, R Frank; Martin, Thomas; Chhabra, Saurabh; Usmani, Saad Z; Jagannath, Sundar; Callander, Natalie S; Berdeja, Jesus G; Kang, Yubin; Vij, Ravi; Godby, Kelly N; Malek, Ehsan; Neppalli, Amarendra; Liedtke, Michaela; Fiala, Mark; Tian, Hong; Valluri, Satish; Marino, Jennifer; Jackson, Carolyn C; Banerjee, Arnob; Kansagra, Ankit; Schecter, Jordan M; Kumar, Shaji; Hari, Parameswaran.
Afiliação
  • Costa LJ; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL. Electronic address: ljcosta@uabmc.edu.
  • Lin Y; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Cornell RF; Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN.
  • Martin T; Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Chhabra S; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
  • Usmani SZ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute-Atrium Health, Charlotte, NC.
  • Jagannath S; Department of Medicine, Mount Sinai Medical Center, New York, NY.
  • Callander NS; Carbone Cancer Center, University of Wisconsin, Madison, WI.
  • Berdeja JG; Center for Blood Cancers, Sarah Cannon Research Institute, Nashville, TN.
  • Kang Y; Department of Medicine, Duke University School of Medicine, Durham, NC.
  • Vij R; Department of Medicine, Oncology Division, Washington University School of Medicine in St Louis, St Louis, MO.
  • Godby KN; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.
  • Malek E; Seidman Cancer Center, University Hospitals, Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
  • Neppalli A; Department of Medicine, Medical University of South Carolina, Charleston, SC.
  • Liedtke M; Department of Medicine, Division of Hematology, Stanford University, Stanford, CA.
  • Fiala M; Department of Medicine, Oncology Division, Washington University School of Medicine in St Louis, St Louis, MO.
  • Tian H; Clinical Development, Cellular Therapy Program, Janssen R&D, Raritan, NJ.
  • Valluri S; Market Access, Janssen Global Services, Raritan, NJ.
  • Marino J; Clinical Research, Early Oncology Development, Janssen R&D, Spring House, PA.
  • Jackson CC; Clinical Development, Cellular Therapy Program, Janssen R&D, Raritan, NJ.
  • Banerjee A; Clinical Research, Early Oncology Development, Janssen R&D, Spring House, PA.
  • Kansagra A; Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX.
  • Schecter JM; Clinical Development, Cellular Therapy Program, Janssen R&D, Raritan, NJ.
  • Kumar S; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Hari P; Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
Clin Lymphoma Myeloma Leuk ; 22(5): 326-335, 2022 05.
Article em En | MEDLINE | ID: mdl-34840088
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article